Unity Biotechnology Faces Dissolution After Nasdaq Delisting

Once-promising biotech company winds down operations after failing to develop successful age-related disease treatments.

Mar. 27, 2026 at 1:55am

Got story updates? Submit your updates here. ›

Unity Biotechnology, Inc., a biotechnology company focused on developing therapeutics to slow, halt, or reverse diseases of aging, has faced significant setbacks in recent years. After being delisted from the Nasdaq stock exchange and being identified as a public shell by regulators, Unity's board has approved a plan of dissolution, with the company expecting no distributions to shareholders after claims and obligations are resolved.

Why it matters

Unity Biotechnology's downfall highlights the challenges faced by biotechnology companies working on complex, long-term research and development projects targeting age-related diseases. The company's inability to bring any of its senolytic and senescence-modulating therapies to market underscores the difficulties in translating promising scientific concepts into successful commercial products.

The details

Unity Biotechnology had concentrated its R&D on the biology of cellular senescence and its role in age-related diseases, with a focus on ophthalmology and neurological conditions. The company's lead investigational compound, UBX1325, showed promising results in early-stage clinical trials for diabetic macular edema. However, Unity was unable to advance UBX1325 or any of its other pipeline candidates, leading to a substantial reduction in force, limited operations, and minimal continued investment in developing revenue-producing assets.

  • On June 27, 2025, Unity reported that Nasdaq had determined the company no longer had an operating business and viewed it as a public shell.
  • On July 9, 2025, Unity's common stock was suspended from trading on Nasdaq and began being quoted on the OTC Pink Marketplace under the symbol UNBX.
  • On August 6, 2025, Nasdaq formally notified the removal of Unity Biotechnology's common stock from listing and registration under Section 12(b) of the Securities Exchange Act of 1934.

The players

Unity Biotechnology, Inc.

A biotechnology company that had focused on developing therapeutics to slow, halt, or reverse diseases of aging, with a emphasis on senescence biology and age-related disease mechanisms.

UBX1325

Unity's lead investigational compound, a potent small molecule inhibitor of BCL-xL that was designed to selectively eliminate senescent cells from diseased tissue.

Jocasta Neuroscience, Inc.

A company that has a global license agreement with Unity for the company's alpha-Klotho biologic for neurological indications, with the potential for development and approval milestones and sales-based royalties.

Got photos? Submit your photos here. ›

What’s next

Unity Biotechnology's shareholders will vote on the company's plan of dissolution at a special meeting on September 18, 2025. If approved, the company will proceed with the liquidation and winding down of its operations.

The takeaway

Unity Biotechnology's downfall serves as a cautionary tale for biotechnology companies pursuing high-risk, long-term research and development projects. The company's inability to bring any of its senolytic and senescence-modulating therapies to market highlights the challenges in translating promising scientific concepts into successful commercial products, even for well-funded and well-intentioned organizations.